Literature DB >> 11909988

Dopamine agonists and sleep in Parkinson's disease.

Charles R Cantor1, Matthew B Stern.   

Abstract

Dopaminergic therapy is increasingly recognized as a cause of excessive daytime sleepiness in patients with PD. This adverse effect may be a dose-related phenomenon that is somewhat more likely to occur with dopamine agonists than with levodopa, although all dopaminergic drugs can be sedating. However, medication effect is only one of several causes of somnolence in PD. Other factors include age-related changes in sleep quality, nocturnal motor disturbances, primary sleep disorders such as sleep apnea, medication-induced sleep disruption, and concurrent medical illnesses. There is also increasing evidence that the disease process itself may affect the control of the sleep-wake cycle. Although we have characterized the sleep disturbances in PD, further investigation is needed to define their prevalence and etiology, particularly with respect to the role of dopamine and dopaminergic agents. Clinicians should be alert to the complaint of excessive sleepiness in their patients and should attempt to identify and treat the underlying causes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11909988     DOI: 10.1212/wnl.58.suppl_1.s71

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.

Authors:  Geoffrey B Varty; Robert A Hodgson; Annamarie J Pond; Michael E Grzelak; Eric M Parker; John C Hunter
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

2.  Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression.

Authors:  Sujay Basu; Dinesh A Barawkar; Vidya Ramdas; Minakshi Naykodi; Yogesh D Shejul; Meena Patel; Sachin Thorat; Anil Panmand; K Kashinath; Rajesh Bonagiri; Vandna Prasad; Ganesh Bhat; Azfar Quraishi; Sumit Chaudhary; Amol Magdum; Ashwinkumar V Meru; Indraneel Ghosh; Ravi K Bhamidipati; Amol A Raje; Vamsi L M Madgula; Siddhartha De; Sreekanth R Rouduri; Venkata P Palle; Anita Chugh; Narayanan Hariharan; Kasim A Mookhtiar
Journal:  ACS Med Chem Lett       Date:  2017-07-05       Impact factor: 4.345

Review 3.  Lewy Body Degenerations as Neuropsychiatric Disorders.

Authors:  Jared T Hinkle; Gregory M Pontone
Journal:  Psychiatr Clin North Am       Date:  2020-04-08

4.  Sleep disturbances associated with Parkinson's disease.

Authors:  Keisuke Suzuki; Masayuki Miyamoto; Tomoyuki Miyamoto; Masaoki Iwanami; Koichi Hirata
Journal:  Parkinsons Dis       Date:  2011-08-17

5.  Tremor and clinical fluctuation are related to sleep disorders in Chinese patients with Parkinson's disease.

Authors:  Hongyan Zhou; Cunzhou Shen; Jie Chen; Hao Qian; Yifan Zheng; Yanmei Liu; Wenbiao Xian; Zhong Pei; Ling Chen
Journal:  Transl Neurodegener       Date:  2014-10-22       Impact factor: 8.014

6.  Bright light improves sleep in patients with Parkinson's disease: possible role of circadian restoration.

Authors:  Takuyuki Endo; Ritsuko Matsumura; Isao T Tokuda; Tomoko Yoshikawa; Yasufumi Shigeyoshi; Koichi Node; Saburo Sakoda; Makoto Akashi
Journal:  Sci Rep       Date:  2020-05-14       Impact factor: 4.379

Review 7.  Quality of life in Parkinson's disease.

Authors:  J A Opara; W Brola; M Leonardi; B Błaszczyk
Journal:  J Med Life       Date:  2012-12-25

8.  Sleep disturbances in Parkinson's disease patients and management options.

Authors:  Daniel O Claassen; Scott J Kutscher
Journal:  Nat Sci Sleep       Date:  2011-12-01

9.  Sleep problems in Parkinson's disease: a community-based study in Norway.

Authors:  Elisabeth Svensson; Antoine G Beiske; Jon Håvard Loge; Kornelia K Beiske; Børge Sivertsen
Journal:  BMC Neurol       Date:  2012-08-10       Impact factor: 2.474

Review 10.  Effects of Deep Brain Stimulation on Sleep-Wake Disturbances in Patients with Parkinson's Disease: A Narrative Review.

Authors:  Yu Jin Jung; Han-Joon Kim; Sun Ha Paek; Beomseok Jeon
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.